Suvaxyn CSF Marker


classical swine fever vaccine (live recombinant)

This medicine is authorised for use in the European Union.


This is a summary of the European public assessment report. Its purpose is to explain how the assessment done by the Committee for Medicinal Products for Veterinary Use (CVMP) on the basis of the documentation provided, led to the recommendations on the conditions of use.

This document cannot replace a face-to-face discussion with your veterinarian. If you need more information about your animal’s medical condition or treatment, contact your veterinarian. If you want more information on the basis of the CVMP recommendations, read the scientific discussion (also part of the EPAR).

This EPAR was last updated on 27/11/2019

Authorisation details

Product details
Suvaxyn CSF Marker
Agency product number
Active substance
live Recombinant E2 gene deleted Bovine Viral Diarrhoea Virus containing Classical Swine Fever E2 (CP7_E2alf)
International non-proprietary name (INN) or common name
classical swine fever vaccine (live recombinant)
Anatomical therapeutic chemical veterinary (ATCvet) codes
Publication details
Marketing-authorisation holder
Zoetis Belgium SA
Date of issue of marketing authorisation valid throughout the European Union
Contact address
Rue Laid Burnait, 1
1348 Louvain-la-Neuve

Product information

11/11/2019 Suvaxyn CSF Marker - EMEA/V/C/002757 - R/0006


Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

  • classical swine fever virus
  • Live viral vaccines

Therapeutic indication

For active immunisation of pigs from 7 weeks of age onwards to prevent mortality and reduce infection and disease caused by classical swine fever virus (CSFV).

Onset of immunity: 14 days.

Duration of immunity: at least 6 months.

Assessment history

How useful was this page?

Add your rating